

EPS 23x

4686972000	sobi.com		Solna, SWEDEN Inc 2001		MGMT owns --									
EPS Rank 37														
Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. It operates through the Haematology, Immunology, and Specialty Care segments. The Haematology segment focuses on haemophilia medicines Elocta and Alprolix. The immunology segment offers treatment for serious, disabling, and life threatening diseases. The Specialty Care segment specializes in the treatment of genetic and metabolic diseases. The company was founded in 2001 and is headquartered in Solna, Sweden. LESS														
ANNUAL - DEC END	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024 Estimate	2025 Estimate			
EPS SEK	0.23	2.86	4.08	8.57	10.78	10.52	8.67	8.52	7.47	9.69	14.72			
CASH FLOW/SHR SEK	1.81	1.22	4.72	7.38	11.79	16.73	17.60	14.93	13.71	18.24	21.88			
PRETAX MARGIN %	3%	20%	24%	34%	30%	28%	21%	18%	13%	2022-24 -8% (13 Stability)	2024-26 18%			
RETURN ON EQUITY %	1%	16%	19%	31%	25%	18%	12%	11%	8%	2020-24 -6% (13 Stability)	2024-26 13%			
SALES % CHANGE	24%	61%	25%	40%	56%	7%	2%	21%	18%	COMP RATING 88	SMR RATING A			
SALES (MIL) SEK	3,228	5,204	6,511	9,139	14K	15K	16K	19K	22K	INV T/O 2.2x 45				
WEEKLY	Aug 30	Sep 6	Sep 13	Sep 20	Sep 27	Oct 4	Oct 11	Oct 18	Oct 25	DEBT %	2021-23	39%	12%	34%
DATAGRAPH RATING	63	55	62	60	60	59	59	59	61	TAX RATE	2021-23	19%	21%	18%
AVG DAILY VOL (000)	349	345	351	402	386	389	390	394	401	BACKLOG	2021-23	--	--	--
UP/DOWN VOLUME	2.0	1.8	2.0	1.5	1.6	1.3	1.3	1.5	1.5	R & D	12.30%	BK VAL 3.48x '23		
ACCUM/DIST RATING	33	34	38	19	21	6	3	13	27	DIV SEK	None	DIV GR RT--		
RELATIVE STRENGTH	77	78	82	79	80	71	71	70	79	BETA	0.68(8.00)	ALPHA 0.12 (0.07)		
GROUP RANK	31	37	28	21	21	24	22	23	14	2023 EMPLOYEES	1,772	(14%)		

47.83
43.48
39.13
34.78
30.43
26.09
21.74
20.00
18.26
16.52

14.78
13.04
11.30
10.43
9.57
8.26
7.39
6.33
5.65
5.22
4.78
4.35
3.91
3.48
3.04
2.61
2.17
2.00
1.83
1.65

LOG VOLUME
9M
6M
2.5M
+25%

FINANCIALS	Sep 20	Dec 20	Mar 21	Jun 21	Sep 21	Dec 21	Mar 22	Jun 22	Sep 22	Dec 22	Mar 23	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	P/E	55	
EPS (SEK)	0.90	4.87	2.26	0.87	1.53	4.02	1.76	0.83	1.46	4.47	3.44	0.71	0.30	3.02	2.35	0.66	2.54	4.44e	2.89e	1.94e	2024 Est.:	35.8	
EPS % CHANGE	-49%	+10%	-41%	-5%	+70%	-17%	-22%	-5%	-5%	+11%	+95%	-14%	-79%	-32%	-32%	-7%	2.54	+47%e	+23%e	+194%e	2025 Est.:	23.5	
SALES (MIL SEK)	2,970.0	4,581.0	3,661.0	3,211.0	3,761.0	4,896.0	4,925.0	3,876.0	3,999.0	5,991.0	5,239.0	4,872.0	5,168.0	6,844.0	6,256.0	5,442.0	7,332.7e	6,307.3e	6,159.0e	5-yr High:	47		
SALES % CHANGE	+1%	-6%	-21%	+5%	+27%	+7%	+35%	+21%	+6%	+22%	+6%	+26%	+29%	+14%	+19%	+12%	7,332.7e	+7%e	+1%e	+13%e	5-yr Low:	11	
EPS % SURPRISE	-10.6%	+15.4%	-9.5%	+39.1%	+4.3%	+23.5%	+27.8%	+15.3%	+10.1%	+6.0%	+5.9%	+39.0%	+46.7%	-15.7%	+0.3%	-13.6%	6,307.3e				vs Ind. Avg:		
FUNDS	388	374	364	340	310	265	294	584	699	781	803	832	829	873	941	920							
SHARES HELD BY FUNDS	88M	68M	66M	58M	48M	38M	47M	61M	66M	66M	67M	66M	75M	88M	95M	94M							

OH -1% LOG (Fixed) PRICE

Europe Long +11.10% in 9.6 WKS

346.40 SEK
+27.60 +8.66%

79 B+